CME Presentations

Nasal Polyps


Presentations


Speakers


CME Information

Global LogoPQH Logo

Multidisciplinary Approach to the Management of CRS with Refractory Nasal Polyps: ENT, Allergist, and Patient Partnerships to Enhance Care and QoL

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA)

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi

LIVE RELEASE DATE

Friday, October 21 from 11:00 AM-12:00 PM ET.

TARGET AUDIENCE

The target audiences for the proposed HCP activity are specialty NPs and PAs, Allergists, Immunologists, ORLs/ENTs, Specialist NPs and PAs

STATEMENT OF NEED/PROGRAM OVERVIEW

Many patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who fail first-line treatment or are ineligible for systemic corticosteroids undergo functional endoscopic sinus surgery (FESS), which has high associated costs, a likelihood of recurrence, and potential complications. However, new evidence supports the efficacy, tolerability, impact on quality of life, and place in treatment of targeted biologics approved for the management of CRSwNP.

Join an expert panel of clinicians to review the underlying pathophysiology of CRSwNP and the heavy disease burden patients with recurrent nasal polyps experience. Approvals of monoclonal antibodies targeting T2 inflammation offer additional options for patients. Panelists will clarify the place of FESS and biologic agents in the treatment of CRSwNP refractory to standard treatments, of recurring nasal polyps after surgery, and in people who cannot receive systemic steroids. Enhanced partnerships between allergists and ear, nose, and throat specialists, along with greater inclusion of each patient’s voice in care, can ensure more patient-centered and effective treatment of CRSwNP.

Do you have patients with nasal polyps who could benefit from related education on the latest treatment strategies and advances? Direct your patients to MedLive.com to access the activity, “Breathe, Finally: Practical, Proactive Approaches to Receive Personalized Care for Your Nasal Polyps.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Describe the burden of disease faced by patients with recurrent NPs or those who are not eligible for systemic corticosteroids
  • Summarize data documenting the efficacy and safety of new T2 inflammation targeted biologic agents, including impacts on QoL and bothersome symptoms, in people with refractory NPs and recurrent NPs after FESS, as well as those ineligible for systemic corticosteroids
  • Recognize the place of biologic agents targeting T2 inflammation in the management of patients with NPs
  • Describe strategies to engage patients with NPs in shared-decision making to enhance access to patient-centered care and improve patient satisfaction and QoL

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Dr. John Bosso
Clinical Professor
Division of Rhinology
Department of Otorhinolaryngology: Head and Neck Surgery
Perelman School of Medicine at The University of Pennsylvania
Research Grant: Cumberland Pharma, Optinose Advisory Boards: Novartis, Sanofi/Regeneron, GSK
Dr. Noam A. Cohen, MD, PhD
Professor of Otorhinolaryngology – Head and Neck Surgery
Perelman School of Medicine at The University of Pennsylvania
Owner/Co-Owner Founder/Co-Founder: 4 Sinuses LLC (consulting company)
Consulting Fee: AstraZeneca, GlaxoSmithKline, OysterPoint, Sanofi/Regeneron
Stock Option Holder: OysterPoint
Royalty: GeneOne Life Sciences

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Lauren Sinclair Nothing to disclose
Eve Wilson Nothing to disclose
Caroline Laurendeau Nothing to disclose
Jack Vielbig- Patient with sinus and Nasal polyps Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.

Moving Toward a Targeted Approach for Nasal Polyps


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Summarize the disease burden experienced by patients with NPs
  • List the limitations of traditional interventions for NPs, including oral or nasal steroids, antibiotics, and surgery
  • Explain the rationale for locally and immunologically targeted approaches to NP management
  • Summarize the efficacy and safety of new and emerging therapies with new mechanisms of action and/or modes of administration for people with NPs
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the Asthma and Allergy Foundation of America (AAFA).

This activity is supported by an independent medical education grant from OptiNose US Inc, Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Friday, July 30, 2021 from 3:00 – 4:00pm ET

Enduring Material

The enduring material will be available from July 30, 2021 to July 30, 2022.

TARGET AUDIENCE

The intended audience for this activity are otorhinolaryngologists (ORLs), allergists, primary care physicians, advanced practitioners (nurse practitioners and physician assistants), and nurses.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
John V. Bosso, MD
Clinical Professor
Division of Rhinology
Deptartment of Otorhinolaryngology: Head and Neck Surgery
University of Pennsylvania
Perelman School of Medicine
Consulting Fees (e.g., advisory boards): GSK, Novartis, Sanofi-Regeneron, AstraZeneca
Contracted Research: OptiNose US Inc
Sanaz Eftekhari
Vice President, Corporate Affairs and Research
Asthma and Allergy Foundation of America
Nothing to disclose
Zachary M. Soler, MD, MSc
Associate Professor of Otolaryngology Head Neck Surgery
Medical University of South Carolina
Consulting Fees (e.g., advisory boards): GSK, Lyra, Novartis, OptiNose US Inc, Sinusonic

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@ImmunologyLive.com.